Utilization of oral hypoglycemic agents in a drug-insured U.S. population.

Boccuzzi, S J; Wogen, J; Fox, J; Sung, J C; Shah, A B; Kim, J

Boccuzzi, S J; Wogen, J; Fox, J; Sung, J C; Shah, A B; Kim, J.

Affiliation

Boccuzzi SJ; The Institute for Effectiveness Research, Bridgewater, New Jersey. Novartis Pharmaceutical Corporation, East Hanover, New Jersey 08807, USA. stephen_boccuzzi@mmmc-tier.com

Diabetes Care ; 24(8): 1411-5, 2001 Aug.

Article in En | MEDLINE | ID: mdl-11473078

Subject(s)

Diabetes Mellitus, Type 2/drug therapy; Hypoglycemic Agents/economics; Hypoglycemic Agents/therapeutic use; Insurance, Pharmaceutical Services/statistics & numerical data; Thiazolidinediones; Carbamates/therapeutic use; Chromans/therapeutic use; Cohort Studies; Databases as Topic; Diabetes Mellitus, Type 2/economics; Enzyme Inhibitors/therapeutic use; Glycoside Hydrolase Inhibitors; Humans; Longitudinal Studies; Managed Care Programs; Metformin/therapeutic use; Piperidines/therapeutic use; Retrospective Studies; Sulfonylurea Compounds/therapeutic use; Thiazoles/therapeutic use; Time Factors; Troglitazone; United States

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Thiazolidinediones / Diabetes Mellitus, Type 2 / Hypoglycemic Agents / Insurance, Pharmaceutical Services Type of study: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limits: Humans Country/Region as subject: America do norte Language: En Journal: Diabetes Care Year: 2001 Document type: Article

Search on Google

XML

PubMed Links